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Asthma is a chronic inflammatory disease of the airways, characterized by the presence of variable and recurring respiratory symptoms, airflow limitation, and airway 
hyper-responsiveness [1]. All children with wheezing do not have 
asthma, as small children might develop wheezing even with 
lower respiratory infections due to small airway caliber. Asthma 
can remain undiagnosed in early childhood [1].
Maximal expiratory flow-volume curves are considered the 
gold standard for the assessment of lung function in children with 
asthma [2]. Regular assessment of pre- and post-bronchodilator 
forced expiratory volume in one second (FEV1) might help to 
identify children at risk for developing a progressive decline in 
airflow [3]. Epidemiological studies have consistently shown a 
tracking of FEV1 and FEV1/forced vital capacity (FVC) ratio from 
childhood to adulthood [2]. Children with persistent wheezing 
phenotypes have more lung function impairment compared 
with other phenotypes [4,5]. In school-aged children, objective 
measurement of lung functions by spirometry is essential for 
evaluation of asthma, as symptoms alone are not reliable [6].
Persistent asthma is defined by National Asthma Education 
and Prevention Program (NAEPP) as the presence of daytime 
asthma symptoms and needs for reliever drugs on more than 
2 days per week, nighttime awakenings more than twice in a 
month and interference with normal activity [1]. Children with 
persistent asthma are treated with controller drugs, and inhaled 
corticosteroids (ICS) are the most effective and commonly used 
drug [1]. If the patient has good control of asthma symptoms for 
6 months, ICS are stepped down. Global initiative for asthma 
guideline recommends that if the child remains symptom 
free on lowest dose of ICS and does not have any risk factor 
for exacerbation or fixed airway obstruction, ICS might be 
discontinued. However, the same guideline does not recommend 
discontinuation in adults with asthma [7]. Long-term cessation of 
ICS treatment is rarely successful in adults but might be achieved 
in children [8].
ICS treatment can be discontinued in a large group of children 
who initially had persistent asthma symptoms. Most of these 
children may remain asymptomatic, though some may develop a 
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Background: Asthma treatment guidelines recommend that inhaled corticosteroids (ICS) can be stopped in children if they remain 
asymptomatic on its lowest dose. However, the effect of stopping steroids on their pulmonary function largely remains unknown. 
Objective: The objective of the study was to compare the lung function parameters of children with persistent asthma, who were 
treated with ICS for at least 1 year and are now remaining asymptomatic after stopping them for ≥1 year (children who outgrew 
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design was cross-sectional comparative study, and it was conducted in the pediatric asthma clinic of a tertiary level teaching hospital 
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remaining asymptomatic after stopping ICS for ≥1 year and 54 children in same age group without asthma. Spirometry was done 
in both groups. Post-bronchodilator reversibility testing was done for children with asthma. Results: The median values of forced 
expiratory volume in one second (FEV1), FEV1%, FEV1/forced vital capacity (FVC) ratio, peak expiratory flow (PEF), PEF%, 
forced expiratory flow 25-75 (FEF25-75), and FEF25-75% were observed to be significantly lower in children who outgrew asthma 
symptoms, when compared with children without asthma. A statistically significant number of children who outgrew their asthma 
had FEV1% <80%, FEV1/FVC ratio <80%, PEF% <80%, and FEF25-75% <80% when compared to children without asthma. 
After inhalation of short-acting beta-agonist, 18 children (33.3%) who had outgrown asthma symptoms had FEV1 reversibility 
more than 12%. Conclusion: The pulmonary functions of children with bronchial asthma who were remaining asymptomatic for 
more than 1 year after stopping ICS were significantly lower than children without asthma.
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recurrence of symptoms later in life. The aim of the study was to 
compare the lung function parameters of children with persistent 
asthma, treated with ICS for at least 1 year and now remaining 
free of symptoms after stopping treatment for ≥1 year, with those 
in the same age group without asthma.
MATERIALS AND METHODS
This cross-sectional comparative study was conducted in the 
pediatric asthma clinic of a tertiary level teaching hospital in South 
India over a period of 1 year from August 2017 to July 2018. The 
study population consisted of two groups: Group 1 consisted of 
children in the age group of 6–18 years with persistent asthma 
(by NAEPP classification), who were treated with ICS for at least 
1 year and are now remaining free of symptoms after stopping 
treatment for ≥1 year. These children were referred as those who 
outgrew their asthma symptoms for descriptive purpose. Group 2 
consisted of healthy children in the age group of 6–18 years 
without asthma.
Children with intermittent asthma or who had other 
comorbidities or acute illness and who were unable to produce 
valid spirograms were excluded from the study. The study was 
approved by the Institutional Ethics Committee. The children 
without asthma were recruited from the school children who 
attended a medical exhibition at our institution. The children 
who outgrew their asthma symptoms were recruited from the 
respiratory clinic. Informed consent from parents and assent from 
children were obtained before recruiting the children for the study.
The parents of children in both groups were interviewed with 
the help of a questionnaire. The questionnaire had four parts, 
including demographic details, frequency, and severity of asthma 
symptoms, family history of asthma and allergic diseases, and 
treatment history. A detailed treatment history including the age 
of initiation of ICS maximum dose needed for control, any other 
drugs needed for control of symptoms, duration of ICS treatment, 
age at stopping treatment, and recurrence of symptoms after 
stopping ICS was obtained from parents of children with asthma. 
The details of the treatment and details about asthma symptoms 
were also obtained from their records in the asthma clinic.
Pulmonary function tests were done using spirometry. All 
children were made to do the forced expiratory maneuver 
using Vitalograph alpha spirometer. Spirogram satisfying the 
American Thoracic Society criteria [9] for a valid test only 
was selected for the study. Global lung function 2012 reference 
values were used [10]. FVC, FEV1, FEV1/FVC ratio, peak 
expiratory flow (PEF), and forced expiratory flow 25-75 
(FEF25-75) were obtained from the volume – time graphs and 
flow-volume loops. FVC, FEV1, PEF, and FEF25-75 were 
also expressed as percentage of predicted values based on age, 
gender, ethnicity, height, and weight. They were termed as 
FVC%, FEV1%, PEF%, and FEF25-75%, respectively. Post-
bronchodilator reversibility testing was also done for children 
who outgrew their asthma symptoms. After doing the baseline 
spirometry, these children were given 200 µg of salbutamol 
using metered dose inhaler with spacer. A repeat spirometry 
was done after 15 min.
The data were analyzed with the help of SPSS 21. The lung 
functions of children who outgrew their asthma were compared 
with the lung functions of children without asthma. The data 
were expressed as Mean (Standard deviation [SD]) for normal 
distribution and median (QD) for skewed distribution. Means 
were compared using t-test. Nonparametric tests were used for 
analyzing skewed data.
RESULTS
The study included 54 children who had outgrown asthma 
symptoms and 54 children without asthma. Their baseline 
characteristics and family history of asthma and allergic diseases 
are described in Table 1. There was a significant difference 
between the two groups with respect to the presence of other 
allergic diseases in the child and presence of asthma or other 
allergic diseases in the first degree relatives.
The group of children who outgrew asthma symptoms was 
analyzed with respect to their initial asthma symptoms and 
treatment needed for symptom control. The mean age at the 
onset of asthma symptoms was 2.43 (1.79) years. The mean age 
at starting ICS was 5 (2.8) years. The steroids were started after 
a mean delay of 2.56 (2.7) years after the onset of symptoms. 
According to NAEPP classification, 23 children (42.6%) had 
mild persistent asthma symptoms and 31 children (57.4%) 
had moderate persistent symptoms. For control of asthma, 
12 children (22%) attained symptom control at low dose of 
ICS (≤200 mcg/day), 29 children (54%) required medium dose 










Male: female 38:16 31:23 0.163
Age (year) 
Mean (SD)
9.69 (2.25) 10.40 (2.93) 0.153
Height (cm) 
Mean (SD)
131.30 (12.39) 136.19 (15.45) 0.073
Weight (kg) 
Mean (SD)
27.8 (8.169) 31.06 (9.85) 0.099
BMI (kg/m2) 
Mean (SD)
15.30 (2.87) 16.21 (3.47) 0.142
Family history of asthma
Yes 7 29 <0.0001
No 47 25
Family history of allergic diseases
Yes 11 35 <0.0001
No 43 19
Other allergic diseases in the child
Yes 4 20 0.0004
No 50 34
SD: Standard deviation, BMI: Body mass index
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(200–400 mcg/day), and 13 children (24%) required high dose 
(>400 mcg/day). Long-acting beta-agonists along with ICS were 
required in 19 children (35%) for symptom control. The average 
duration of ICS use was 3.98 (1.58) years, and the mean age of 
stopping the steroids was 9.06 (3.09) years.
Table 2 describes the median (QD) values of the forced 
expiratory maneuver parameters of the two groups. The median 
values of pulmonary function parameters were significantly lower 
in children who outgrew asthma symptoms when compared with 
children without asthma. Figure 1 is a boxplot comparing FEV1% 
of the two groups. Figure 2 compares the FEF25-75% of the two 
groups.
Expiratory airflow limitation was quantitated by comparing 
the FEV1%, PEF%, and FEF25-75% with predicted values 
based on age, gender, weight, and ethnicity. A value <80% when 
compared to the predicted value was considered as abnormal. 
FEV1/FVC ratio <80% is considered as the parameter, which 
consistently indicates airway obstruction.
Table 3 compares the frequency of abnormal lung function 
values between the two groups. A statistically significant number 
of children who outgrew their asthma had abnormal FEV1%, 
FEV1/FVC ratio, PEF%, and FEF25-75% <80% when compared 
to children without asthma.
Post-bronchodilator reversibility testing was done in the 
group who had outgrown their asthma symptoms. The FEV1, 
PEF, and FEF25-75 values obtained were compared with the 
baseline values. Mean increase in FEV1 after bronchodilatation 
was 110.4 (9.9) ml and 7.67% (0.82%) in children who outgrew 
asthma symptoms. PEF increased by 394.8 (49.4) ml and 16.24% 
(2.4%) and FEF25-75 increased by 432.2 (35.8) ml and 29.7% 
(2.9%) after bronchodilatation.
After inhalation of short-acting beta-agonist, 18 children 
(33.3%) who had outgrown asthma symptoms had FEV1 
reversibility more than 12% or 200 ml. Among them, 7 
children (13%) had post-bronchodilator increase in FEV1 
>15%, which is considered as high reversibility. Nineteen 
children (35%) had PEF reversibility more than 20% and 34 
children (63%) had FEF25-75 reversibility more than 20% 
after bronchodilatation. The improvement in the pulmonary 
function studies after bronchodilatation indicates the presence 
of bronchospasm in these children, even though they do not 
have any symptoms.
The pulmonary functions of the children who outgrew their 
asthma symptoms were further analyzed to look for factors 
associated with abnormal lung function values. The onset of 
asthma symptoms below the age of 3 years was associated with 
persistent post-bronchodilator reversibility in FEV1 by more than 
12% (p=0.026), and presence of other allergic diseases in the child 
was significantly associated with low FEV1 (<80% of predicted) 
(p=0.044). Girls had a lower PEF% than boys (p=0.002). There 
was no significant association between other factors studied and 
abnormal lung function values.
DISCUSSION
The lung function parameters of children who outgrew asthma 
symptoms were significantly lower when compared to children 
without asthma. The median values of FEV1%, median FEV1:FVC 
ratio, PEF%, and FEF25-75 of children who outgrew their asthma 













FVC (L) 1.69 (0.25) 1.57 (0.42) 0.922
FVC% 89 (6.5) 89 (8.5) 0.472
FEV1 (L) 1.52 (0.26) 1.29 (0.34) 0.151
FEV1% 95 (6.5) 84 (8.5) 0.001
FEV1/FVC 
ratio
87.2 (4.1) 84.75 (3.7) 0.000
PEF (L/s) 3.25 (0.68) 3.14 (0.77) 0.124
PEF% 89 (9) 76.5 (13.5) 0.000
FEF25-75 (L/s) 1.93 (0.28) 1.43 (0.32) 0.000
FEF25-75% 92 50 (16.5) 66 (12) 0.000
FVC: Forced vital capacity, PEF: Peak expiratory flow
Figure 1: Boxplot – forced expiratory volume in one s% of children 
without asthma and children who outgrew asthma symptoms
Figure 2: Boxplot – forced expiratory flow 25‑75% of children 
without asthma and children who outgrew asthma symptoms
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symptoms were significantly less than the corresponding median 
values of children without asthma. The lung function parameter 
with the greatest difference between the two groups was FEF25-
75, which indicates small airway obstruction. We were able to 
demonstrate a statistically significant increase in all the lung 
function parameters after inhalation of 200 mcg salbutamol in 
the group of children who outgrew asthma symptoms. In the 
present study, 33.3% had a post-bronchodilator increase in FEV1 
by >12% or 200 ml, which is the hallmark of reversible airway 
obstruction. This demonstrates that even though these children 
are remaining asymptomatic, they still have bronchial obstruction 
and smooth muscle spasm, demonstrable by spirometry.
There is paucity of similar studies in literature, which have 
compared lung functions of children who currently do not have 
asthma symptoms with children without asthma. A birth cohort 
study by Sears et al. compared the lung function in patients 
with persistent asthma (both in remission and symptomatic), 
intermittent asthma and transient wheezing with children without 
asthma [11]. They found that the mean difference in FEV1 of 
persons with persistent wheezing in remission was 5% lesser than 
persons without asthma at the age of 26 years [11]. They found 
no significant difference between FEV1:FVC ratio of patients in 
remission and persons without asthma. The mean FEV1/FVFC 
ratio of persons in remission was lower by 0.8 in males and 2.3 
in females when compared to persons without asthma in their 
study [11].
Morgan et al. found that the FEV1 of infrequent persistent 
wheezers was 66 ml (p=0.02) lower than children without asthma 
[12]. Henderson et al. found that FEV1 of children without 
asthma was higher by 0.14 SD units than children with infrequent 
wheezing at the age of 8–9 years [4]. They also found that FEF25-
75 of children without asthma was higher by 0.18 SD units than 
children with infrequent wheezing at the age of 8–9 years [4]. In 
the birth cohort study by Stern et al., lung functions were studied 
at 22 years of age. They found that the post-bronchodilator 
increase in FEV1:FVC ratio was 0.5 in persons with inactive 
asthma [13,14].
Agertoft and Pedersen found that the delay in initiating 
treatment after the onset asthma symptoms significantly affected 
the lung functions. Children who received budesonide after 5 years 
from the onset of symptoms had a lower FEV1% (96%) than 
children who were initiated within 2 years of onset of symptoms 
(101%) [15]. In the present study, delay in initiation of treatment 
was not significantly associated with abnormal lung function. 
The onset of symptoms below 3 years and the presence of other 
allergic diseases were found to have significant association with 
abnormal lung functions.
A recent study comparing the use of 200 and 400 µg 
of salbutamol for reversibility testing in Korean children, 
found that the use of 400 µg of salbutamol produces more 
bronchodilatation [16]. Hence, the significant post-bronchodilator 
reversibility demonstrated with 200 µg of salbutamol in the present 
study implies that more children might have bronchodilator 
reversibility at the standard dose of 400 µg of salbutamol. The 
degree of reversibility has been correlated with the degree of 
airway inflammation [17]. Children with high post-bronchodilator 
reversibility are at increased risk for airway remodeling and 
hence loss of lung function overtime [18]. Spirometry is a poorly 
utilized tool in management of pediatric asthma [19]. Stout et al. 
have demonstrated that addition of lung functions to the symptom 
frequency will result in reclassification of asthma symptoms to a 
higher severity in a significant proportion of patients [20].
The authors suggest that a lung function study should be done 
before stopping controller medications in children with asthma, 
and controllers should be stopped only if lung functions, including 
post-bronchodilator reversibility is normal. The sub-group of 
children in whom the controller treatment is stopped should be 
kept under follow-up, with yearly lung function studies. They 
need to be assessed to see if the growth in their lung function is 
within normal limits. Treating physicians should also be on the 
lookout for an early or rapid decline in lung functions with age.
This study was not designed to identify the risk factors 
associated with low lung functions in children who outgrew 
their asthma. Further studies with higher sample size and 
detailed evaluation of risk factors will help to identify the factors 
associated with low lung function parameters in children who had 
outgrown their asthma symptoms.
CONCLUSION
The lung function parameters of children who were remaining 
asymptomatic for more than 1 year after stopping ICS were 
significantly lower than the parameters of children without 
asthma. Total 33% of the children, who remained asymptomatic 
after stopping ICS, had a post-bronchodilator increase in FEV1 
by >12% or 200 ml, which is an indicator of reversible airway 
obstruction, the hallmark of asthma.
Table 3: Comparison of abnormal pulmonary function parameters 











>80 44 41 0.639
<80 10 13
FEV1
>80 49 36 0.0056
<80 5 18
FEV1/FVC ratio
>80 53 44 0.008
<80 1 10
PEF
>80 44 23 <0.0001
<80 10 31
FEF25-75
>80 39 12 <0.0001
<80 15 42
FVC: Forced vital capacity, PEF: Peak expiratory flow
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